Can ulipristal acetate (Accessa) be used to shrink fibroids and then allow pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Important Clarification: Accessa is NOT Ulipristal Acetate

You cannot use Accessa to shrink fibroids before pregnancy because Accessa is a completely different medical device used for radiofrequency ablation of fibroids, not ulipristal acetate (the medication that shrinks fibroids). The confusion in your question appears to stem from mixing up these two distinct treatments.

What is Accessa?

Based on the FDA drug label provided 1, "Accessa" refers to SUBSYS (fentanyl sublingual spray), which is a potent opioid pain medication used for breakthrough cancer pain—it has absolutely nothing to do with fibroid treatment. The drug label explicitly states it may cause fetal harm during pregnancy 1.

What You're Actually Asking About: Ulipristal Acetate (UPA)

If you're asking whether ulipristal acetate can shrink fibroids before attempting pregnancy, here's the evidence-based answer:

The Critical Problem: UPA is Not Available in the United States

Ulipristal acetate is NOT approved for fibroid treatment in the United States and has been withdrawn from most global markets due to hepatotoxicity concerns 2. Reports of severe liver injury, including cases requiring liver transplantation, led to marketing suspension and eventual withdrawal 2, 3.

Evidence for Pregnancy After UPA (When It Was Available)

While UPA was available in Europe and Canada, evidence showed:

  • UPA effectively reduces fibroid volume (33-72% reduction) and controls bleeding 4, 5, 6, 7
  • Successful pregnancies have been reported after UPA treatment in case reports and small studies 8, 9, 10, 11
  • One case series showed pregnancy rates of 57.6% after UPA treatment before IVF, with 50% ongoing pregnancy rates 9
  • Endometrial changes (PAEC) are reversible within 3 months after stopping treatment 4

Current Recommendations for Fibroid Management Before Pregnancy

Since UPA is unavailable, the 2024 ACR guidelines 2 recommend:

For women desiring pregnancy with symptomatic fibroids:

  1. Surgical options remain first-line:

    • Hysteroscopic myomectomy for submucosal fibroids
    • Laparoscopic or open myomectomy for intramural/subserosal fibroids
    • Less than half of women achieve pregnancy after myomectomy, with even fewer live births 2
  2. Preoperative medical therapy (if surgery planned):

    • GnRH agonists (leuprolide) or GnRH antagonists (elagolix, relugolix) can shrink fibroids before surgery 2, 5
    • These reduce fibroid volume by 45-67% and increase preoperative hemoglobin 5
    • Critical limitation: Fertility is suppressed during treatment, and symptoms rapidly recur after stopping 2
    • Used for short courses only (typically 3 months) before surgery 2
  3. Important caveat: GnRH agonists/antagonists are NOT used to shrink fibroids for spontaneous conception—they suppress ovulation and are only used preoperatively 2

Bottom Line

You cannot use Accessa (which is fentanyl) to shrink fibroids. If you're seeking medical therapy to shrink fibroids before pregnancy, ulipristal acetate is not available in the US due to liver toxicity concerns 2, 3. The current standard approach is either:

  • Proceeding with myomectomy (surgical removal) if fibroids are causing symptoms or infertility
  • Using GnRH agonists/antagonists for 3 months before planned surgery (not for spontaneous conception attempts)

For women desiring pregnancy, surgical myomectomy remains the definitive treatment when fibroids are impacting fertility, though pregnancy rates remain modest even after surgery 2.

References

Guideline

acr appropriateness criteria® management of uterine fibroids: 2023 update.

Journal of the American College of Radiology, 2024

Research

Preoperative medical therapy before surgery for uterine fibroids.

The Cochrane database of systematic reviews, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.